Generic Glumetza Scripts Lupin's Strong US Run

Lupin Ltd. has reported stellar numbers for the fourth quarter ended March 2016, buoyed by US sales of its generic version of Glumetza (metformin HCL extended-release tablets), the Valeant Pharmaceuticals International Inc. drug dumped earlier this year by pharmacy benefits manager, Express Scripts Holding Co.

The fourth quarter saw nine product launches in the US - the most the Indian firm has had so far in a quarter – and while several products contributed to growth, generic Glumetza launched in February was the "most significant" and did extremely well, Lupin's CEO Vinita Gupta told Scrip

"We partnered with Express Scripts and they decided to promote our generic just given the savings that we could bring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

 
• By 

While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By 

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By 

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

More from Scrip

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By 

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By 

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.